PathAI raises $60 million Series B funding to improve cancer diagnosis using artificial intelligence
PathAI, a healthtech startup with mission to improve cancer diagnosis using artificial intelligence, has has raised $60 million in Series B funding to enhance offerings to existing partners, drive continuous improvement of its flagship pathology research platform, meet market demands, and fuel research and development into new tools and medical devices. The round was led by new investor General Atlantic, a leading global growth equity firm, with strong participation from General Catalyst and other existing investors.
Founded in 2016 by Aditya Khosla and Andrew Beck, PathAI’s services solve the most challenging pathology problems faced by the research and pharmaceutical industry. The PathAI platform provides end-to-end automation for reliable, scalable, and cost-effective long-term solutions.Their solutions make discovery scalable.
According to the announcement, the company also plans to use the new capital infusion to fuel its continued expansion as the company seeks to advance the medical discipline of pathology. General Atlantic Managing Director Dr. Michelle Dipp will be joining PathAI’s board of directors as the company advances its mission of offering faster, safer, and more powerful solutions for the diagnosis and sub-typing of diseases like cancer.
“Our goal has been clear since day one – a relentless drive to ensure patients get the right diagnosis and the most effective treatment. We’re looking forward to working with our partners to scale this effective approach across disease areas and around the world,” PathAI co-founder and Chief Executive Officer Dr. Andy Beck said. “The global network and deep expertise in technology and life sciences brought by General Atlantic, alongside the continued support of existing investors like General Catalyst, can only enhance our ability to effect change toward this major, impactful objective.”
“PathAI is a clear leader in the emerging digital pathology industry that is being disrupted by technology and machine learning,” said Dr. Michelle Dipp. “As we remain committed to supporting the next generation of life sciences companies, we’re thrilled to partner with PathAI, which seeks to address critical problems by bringing cutting edge storage, viewing, and AI-enabled analytics to help pathologists make fast, accurate, and consistent diagnoses.
“PathAI’s work could radically improve the accuracy and reproducibility of disease diagnosis and support the development of new medicines to treat those diseases,” said David Fialkow, Managing Director at General Catalyst. “GC is honored to once again back founders, Andy Beck and Aditya Khosla, Chief Business Officer Tiffany Freitas, Chairman Jeff Leiden, and the entire PathAI team. The positive – and global – impact of getting this right cannot be overstated. We think this is the team that has all the potential to bring these game-changing solutions to market.”
This funding round comes as PathAI has secured critical certifications in quality management and information security systems. PathAI’s staff has grown from 25 to more than 60 in the past year, reflecting the company’s investments in machine learning, product development, quality and regulatory affairs, and scientific program management. PathAI has been named one of the best places to work in Boston by the Boston Business Journal and Built in Boston, and key partners like Bristol-Myers Squibb and Novartis have publicly lauded the work they have done with PathAI to advance the state of disease treatment.